| HOME >> BIOLOGY >> TECHNOLOGY |
ATLANTA, Jan. 18 /PRNewswire/ -- Elekta, a world leader in clinical solutions for radiation therapy and radiosurgery, announced today that two sites are utilizing Elekta technology to implement clinical treatments with Volumetric Modulated Arc Therapy (VMAT)*. With the recent CE designation of VMAT in Europe, the way has been cleared for The Royal Marsden Hospital in Sutton, UK and General Hospital Vienna in Austria to treat cancer using Elekta's VMAT solution.
VMAT is a significant improvement to existing advanced radiation therapy techniques, often referred to as IMRT (Intensity Modulated Radiation Therapy) and offers a faster alternative to helical tomotherapy. With Elekta's VMAT technology, the target continuously is radiated while the source of the beam is rotated around the patient in single or multiple arcs. By simultaneously controlling gantry position, gantry speed, leaves of the multi-leaf collimator (MLC), collimator angle and dose rate, a highly conformal dose distribution is created in significantly less time than with today's techniques. With VMAT from Elekta, a treatment session typically can be conducted in five minutes or less, including true 3D imaging to secure the location of the target.
"VMAT is a very promising technique," says Dietmar Georg, Ph.D., head of the Division of Medical Radiation Physics, Department of Radiotherapy, Medical University Vienna/General Hospital Vienna. "The rotational therapy and intensity modulation results in improved dose distribution and high conformality for optimal sparing of normal tissue." Using VMAT, Dr. Georg expects to see a more efficient workflow and faster treatments for patients receiving advanced radiotherapy.
Jim Warrington, head of Radiotherapy Physics at The Royal Marsden
Hospital, says, "With the potential to produce megavoltage X-ray treatments
of the highest quality and efficiency available, we anticipate VMAT will
offer us greater flexibility as a radiotherapy treatment
'/>"/>
| SOURCE Elekta, Inc. Copyright©2008 PR Newswire. All rights reserved |